Schedule 13G ownership disclosure
Gemphire Therapeutics Inc.
Security class unavailable · CUSIP: 36870A108
Event date: 2017-03-10
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 619,957
- Percent of class
- 5.8500%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-17-001681
- Form type
- SC 13G
- Filer
- ADAGE CAPITAL PARTNERS GP, L.L.C.
- CIK
- CIK 1165408
- Filed
- Mar 20, 2017
- Reporting period
- Mar 10, 2017
- Description
- Schedule 13G beneficial ownership